The	O
in	O
vivo	O
properties	O
of	O
STX243	O
:	O
a	O
potent	O
angiogenesis	O
inhibitor	O
in	O
breast	B-Cancer
cancer	I-Cancer
.	O

The	O
steroidal	O
-	O
based	O
drug	O
2	O
-	O
ethyloestradiol	O
-	O
3	O
,	O
17	O
-	O
O	O
,	O
O	O
-	O
bis	O
-	O
sulphamate	O
(	O
STX243	O
)	O
has	O
been	O
developed	O
as	O
a	O
potent	O
antiangiogenic	O
and	O
antitumour	B-Cancer
compound	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
ascertain	O
whether	O
STX243	O
is	O
more	O
active	O
in	O
vivo	O
than	O
the	O
clinically	O
relevant	O
drug	O
2	O
-	O
methoxyoestradiol	O
(	O
2	O
-	O
MeOE2	O
)	O
and	O
the	O
structurally	O
similar	O
compound	O
2	O
-	O
MeOE2	O
-	O
3	O
,	O
17	O
-	O
O	O
,	O
O	O
-	O
bis	O
-	O
sulphamate	O
(	O
STX140	O
)	O
.	O

The	O
tumour	B-Cancer
growth	O
inhibition	O
efficacy	O
,	O
antiangiogenic	O
potential	O
and	O
pharmacokinetics	O
of	O
STX243	O
were	O
examined	O
using	O
four	O
in	O
vivo	O
models	O
.	O

Both	O
STX243	O
and	O
STX140	O
were	O
capable	O
of	O
retarding	O
the	O
growth	O
of	O
MDA	B-Cancer
-	I-Cancer
MB	I-Cancer
-	I-Cancer
231	I-Cancer
xenograft	I-Cancer
tumours	I-Cancer
(	O
72	O
and	O
63	O
%	O
,	O
respectively	O
)	O
,	O
whereas	O
no	O
inhibition	O
was	O
observed	O
for	O
animals	O
treated	O
with	O
2	O
-	O
MeOE2	O
.	O

Further	O
tumour	B-Cancer
inhibition	O
studies	O
showed	O
that	O
STX243	O
was	O
also	O
active	O
against	O
MCF	B-Cancer
-	I-Cancer
7	I-Cancer
paclitaxel	I-Cancer
-	I-Cancer
resistant	I-Cancer
tumours	I-Cancer
.	O

Using	O
a	O
Matrigel	O
plug	O
-	O
based	O
model	O
,	O
in	O
vivo	O
angiogenesis	O
was	O
restricted	O
with	O
STX243	O
and	O
STX140	O
(	O
50	O
and	O
72	O
%	O
,	O
respectively	O
,	O
using	O
a	O
10	O
mg	O
kg	O
(	O
-	O
1	O
)	O
oral	B-Organism_subdivision
dose	O
)	O
,	O
thereby	O
showing	O
the	O
antiangiogenic	O
activity	O
of	O
both	O
compounds	O
.	O

The	O
pharmacokinetics	O
of	O
STX243	O
were	O
examined	O
at	O
two	O
different	O
doses	O
using	O
adult	O
female	O
rats	O
.	O

The	O
compound	O
was	O
orally	B-Organism_subdivision
bioavailable	O
(	O
31	O
%	O
after	O
a	O
single	O
10	O
mg	O
kg	O
(	O
-	O
1	O
)	O
dose	O
)	O
and	O
resistant	O
to	O
metabolism	O
.	O

These	O
results	O
show	O
that	O
STX243	O
is	O
a	O
potent	O
in	O
vivo	O
drug	O
and	O
could	O
be	O
clinically	O
effective	O
at	O
treating	O
a	O
number	O
of	O
oncological	O
conditions	O
.	O

